Alcon has signed a licensing deal with Potentia Pharmaceuticals to develop that company's POT-4 drug to treat age-related macular degeneration. If Alcon decides to continue development of the drug, a separate agreement will allow it to buy the share of Potentia at certain conditions. Alcon will pay royalties to Potentia's ...
Already an Eyewear Intelligence subscriber? Sign in here.
Buying a membership today will give you:
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.